Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of adavosertib in recurrent or persistent uterine serous carcinoma
2020-000138-16Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adavosertib in Serous endometrial adenocarcinoma, sponsored by AstraZeneca. Primary endpoint: Overall Response Rate. Started Aug 2020; status: completed.
02
Drugs
adavosertib
03
Conditions
Serous endometrial adenocarcinoma
Beyond the preview
Go deeper on 2020-000138-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000138-16.